Upcoming: Free Webinar on Patent Process and Strategy – Session 3 of the Master Class on IP by BananaIP and NASSCOM’s KTech CoE on Data Science

Join the third session of the Certificate Master Class on IP to learn about the patent process in India and strategic patent management. The webinar includes presentations from leading patent attorneys and a demonstration of BananaIP’s free AI-based patent drafting tool.

Read more about Upcoming: Free Webinar on Patent Process and Strategy – Session 3 of the Master Class on IP by BananaIP and NASSCOM’s KTech CoE on Data Science

Searching for Patents and Patentability of AI and Software Inventions: Session 2 of the Masterclass on IP

This session of the masterclass explored patentability criteria and search strategies for AI and software inventions. Attendees learned about the patent process, prior art search, and practical considerations for Indian innovators. The session offered valuable guidance on intellectual property for startups.

Read more about Searching for Patents and Patentability of AI and Software Inventions: Session 2 of the Masterclass on IP

Register for Session 2 of the Free Masterclass on Intellectual Property by BananaIP, Ktech Center of Excellence for Data Science and NASSCOM

Session 2 of the Intellectual Property Masterclass by BananaIP and NASSCOM will focus on patents and their relevance for startups. Senior experts will discuss patentability, patent searches, and field-specific rules, addressing all participant questions. The previous session received positive feedback for its clarity and practical approach.

Read more about Register for Session 2 of the Free Masterclass on Intellectual Property by BananaIP, Ktech Center of Excellence for Data Science and NASSCOM

Updated Patent, Trade Mark, Copyright and other Acts

The post offers updated and amended versions of major Indian intellectual property statutes following the abolition of the IPAB. Downloadable resources and detailed amendment summaries are provided for reference.

Read more about Updated Patent, Trade Mark, Copyright and other Acts

Epic Games Sues VR Company, Mankind Pharma Secures Injunction and more

This bulletin examines recent trademark infringement cases in India and abroad, including Mankind Pharma’s injunction and Epic Games’ lawsuit. It also features brand licensing news and updates on geographical indication applications, offering a clear and factual legal analysis.

Read more about Epic Games Sues VR Company, Mankind Pharma Secures Injunction and more

In Support of Prof. Arul Scaria on Compulsory Licensing for COVID Vaccines, Medicines, Diagnostics and other Technologies

The article examines India’s policy on compulsory licensing for COVID-related medical technologies, echoing Prof. Arul Scaria’s critique of current government inaction. It highlights the legal and historical basis for compulsory licensing and argues for its strategic use to ensure public access to vaccines and medicines.

Read more about In Support of Prof. Arul Scaria on Compulsory Licensing for COVID Vaccines, Medicines, Diagnostics and other Technologies

Over 400 patent applications published on an early basis this week, over 1000 patents issued

Indian patent statistics for the week reveal increased early publications and patent grants, alongside a decrease in ordinary publications. The data provides a comprehensive overview of patent activity and design registrations across major Indian cities.

Read more about Over 400 patent applications published on an early basis this week, over 1000 patents issued

Natco withdraws compulsory license, signs agreement with Eli Lilly for Barcitinib; Patent Office notifies extension of timelines and more

Natco Pharma has withdrawn its compulsory license application for Baricitinib following an agreement with Eli Lilly. The Indian Patent Office has extended procedural deadlines, and other significant updates in IP law are discussed, including ongoing litigation and international proposals.

Read more about Natco withdraws compulsory license, signs agreement with Eli Lilly for Barcitinib; Patent Office notifies extension of timelines and more